2012 News Releases

Webcast ImageWebcast
NeuroDerm Q4 and Full Year 2016 Financial Results (Live)
03/30/17 at 8:30 a.m. ET

NeuroDerm Q4 and Full Year 2016 Financial Results
Thursday, March 30, 2017 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
11/20/12NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson’s Disease
Ness Ziona, November 20, 2012 / — NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson’s disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the reduction of motor complications in Parkinso... 
Printer Friendly Version